Carbamazepine Extended-Release Capsules are therapeutically equivalent and substitutable for the brand Carbatrol.
Carbatrol is used to treat certain types of seizures (partial, tonic-clonic, mixed) and certain types of nerve pain (trigeminal and glossopharyngeal neuralgia).
The product will be distributed in the US under the Prasco label.
Prasco CEO Christopher H Arington said Carbamazepine Extended-Release Capsules will provide patients with a therapeutically equivalent product to the brand as a Prasco Authorized Generic.
The financial terms of the agreement, however, have not been revealed.